Eric M. Dube - 06 Jun 2023 Form 4 Insider Report for Reneo Pharmaceuticals, Inc. (OKUR)

Reporting relationship: Director
Issuer ticker: OKUR
Reported as of: 06 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jun 2023, 18:02:20 UTC
Prior SEC filing: 02 Feb 2023
Next SEC filing: 05 Sep 2023
Source filing: View source filing
Reporting owner signature: /s/ Jennifer P. Lam, Attorney-in-Fact

Key filing fact

Eric M. Dube filed Form 4 for Reneo Pharmaceuticals, Inc. (OKUR) on 08 Jun 2023.

Key facts

This page summarizes Eric M. Dube's Form 4 filing for Reneo Pharmaceuticals, Inc. (OKUR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Jun 2023, 18:02.

Change

Previous filing in this sequence was filed on 02 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RPHM transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +17,500
Change %
Price: $0.000000
Shares after: 17,500
Date: 06 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,500
Exercise price: $9.01
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.